Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

AX Semantics Launches Content Generation Software for Pharmaceutical Sector

HIPAA-compliant technology allows pharmaceutical companies to automate the laborious process of writing regulatory Clinical Study Reports on medications and bring them to market up to 40% faster


News provided by

AX Semantics

Jun 02, 2020, 11:00 ET

Share this article

Share toX

Share this article

Share toX

AX Semantics, the easiest way to automate your content production
AX Semantics, the easiest way to automate your content production

SAN FRANCISCO, June 2, 2020 /PRNewswire-PRWeb/ -- AX Semantics, an AI-powered, Natural Language Generation (NLG) market leader, today announced a new range of HIPAA-compliant content generation software for the pharmaceutical sector, which will allow pharmaceutical companies to generate regulatory Clinical Study Reports (CSRs) on medications up to 40% faster by automating 30% of writing the CSR.

"In addition to its effect on human lives and the economy, the coronavirus pandemic has exposed the hurdles pharmaceutical companies must overcome to get medication to patients. These processes are doubtless important to keep medications safe, but they also rely on outdated processes," said Saim Rolf Alkan, CEO and founder of AX Semantics. "Content automation driven by NLG technology connects to the clinical study database and instantly generates HIPAA-compliant, auditable reports that help pharmaceutical companies meet regulatory requirements at a time when getting the right medications and vaccines approved as expeditiously as possible is critical to ensure global public health."

Content automation driven by NLG technology connects to the clinical study database and instantly generates HIPAA-compliant, auditable reports that help pharmaceutical companies meet regulatory requirements at a time when getting the right medications approved quickly is critical to global health."

Post this

AX Semantics Upends the Status Quo.
The most challenging phase of bringing a drug to market is the human drug trial, or Phase III, during which time clinicians must write a CSR that describes the pharmacological impacts and trial outcomes. Typically, data collected from the human drug trials is gathered and medical writing teams manually compile the report, however, this outdated, onerous and time-consuming process can potentially delay life-saving medications from coming to market sooner and cost pharmaceutical companies millions. A capacity challenge also exists. Writing a CSR report typically takes several months to complete, which limits the number of CSRs a team of medical writers can produce annually. Some pharmaceutical companies have tried using templates to overcome the manual writing process challenge, however the templates have been found to be too complex and rigid for the different scenarios the CSR encompasses. For example, acceptable mortality rates can differ significantly depending on the drug that is being trialed: a drug that treats late stage cancer may have a mortality rate of 8%, which is acceptable, but a rate that high for a drug that treats a migraine headache is completely unacceptable. Templates cannot deal with these types of different scenarios, which severely limits their value.

AX Semantics content generation features for pharmaceutical and clinical study reports, include:

  • NLG output based on structured data: allows users to easily configure projects to any structure and import tools and formats including JSON, CSV and Excel, and API for integration into existing systems like Oracle Databases without the need for complex IT projects;
  • Topic and domain independent technology: all types of text can be generated, not just a limited set of topics — in up to 110 different languages;
  • Easy-to-use interface with real-time, multi-user capability and workflows: multiple people can work on a project at the same time, allowing scaled project sizes, while retaining the ability to test and deploy; and
  • Data Protection and Hybrid Cloud Availability: with certifiable processes and infrastructure that can be used for confidential information up to HIPAA/PHI level, and Sarbanes–Oxley/MARisk certifiable processes.

Named one of the world's top five providers of natural language generation platforms by Gartner, and a top emerging company in the NLG market by Forrester, AX Semantics offers a subscription-based service, with fees between $279 and $1699 per month for pharmaceutical companies. A managed service that creates the CSR reporting is also available on top of the self-service platform for new product development purposes and customers that don't have qualified in-house resources by utilizing the global Network of AX Semantics' Managed Service Providers like hmmh (Serviceplan Group), Deloitte and uNaice. An industry first, this fully managed project is available at fixed flat rates with a pricing from $7,999 to $18,999, further reducing ramp up time for the project and minimizing the needed investments. The software is 100% SaaS – everything is available via a web browser, with no programming or IT departments required. Self-service with integrated e-learning allows customers to start automating text within 48 hours, often less. Learn more at [email protected].

About AX Semantics
AX Semantics is an AI-powered, natural language generation (NLG) software company built to address today's biggest content generation challenges. Our sophisticated SaaS-based solution effortlessly creates vast quantities of content at scale - to tackle time-intensive financial reporting and regulatory requirements filings, automate laborious pharmaceutical Clinical Study Reports, fill a news section with earnings reports, sports scores or weather reports, generate 1000s of unique product descriptions for e-commerce brands, produce social media content, and more. We make automated content generation — in more than 110 languages, in a manner of minutes — a reality for customers of all sizes within the finance, pharmaceutical, e-commerce, business and media publishing sectors.

Headquartered in Stuttgart, Germany with an additional office in Sunnyvale, California, AX Semantics is a privately-held company backed by Airbridge Equity Partners. Follow us on social at Twitter, LinkedIn, Facebook and Instagram, or learn more at https://en.ax-semantics.com.

All trademarks contained herein are the property of their respective owners.

SOURCE AX Semantics

Related Links

https://en.ax-semantics.com

Modal title

Saim Rolf Alkan, CEO and founder of AX Semantics
Saim Rolf Alkan, CEO and founder of AX Semantics
Saim Rolf Alkan, CEO and founder of AX Semantics

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.